Metallothionein Alleviates Glutathione Depletion-Induced Oxidative Cardiomyopathy Through CISD1-Dependent Regulation of Ferroptosis in Murine Hearts.
Feng-Juan Li,Shouzhi Fu,Hua Ye,Yi-Han Hu,Jianxin Chen,Jamie R. Privratsky,Wei Yu,Feng Dong,Russel J. Reiter,Maolong Dong,Jun Guo,Jun Ren
DOI: https://doi.org/10.1016/j.ajpath.2024.02.009
IF: 5.77
2024-01-01
American Journal Of Pathology
Abstract:This study was designed to discern the effect of heavy scavenger metallothionein on glutathione (GSH) deprivation -evoked cardiac anomalies and mechanisms involved with an emphasis on ferroptosis. Wildtype and cardiac metallothionein transgenic mice received GSH synthase inhibitor buthionine sulfoximine (BSO; 30 mmol/L in drinking water) for 14 days before assessment of myocardial morphology and function. BSO evoked cardiac remodeling and contractile anomalies, including cardiac hypertrophy, interstitial fi brosis, enlarged left ventricular chambers, deranged ejection fraction, fraction shortening, cardiomyocyte contractile capacity, intracellular Ca 2 + handling, sarcoplasmic reticulum Ca 2 + reuptake, loss of mitochondrial integrity (mitochondrial swelling, loss of aconitase activity), mitochondrial energy de fi cit, carbonyl damage, lipid peroxidation, ferroptosis, and apoptosis. Metallothionein itself did not affect myocardial morphology and function, although it mitigated BSO-provoked myocardial anomalies, loss of mitochondrial integrity and energy, and ferroptosis. Immunoblotting revealed downregulated sarco(endo)plasmic reticulum Ca 2 + -ATPase 2a, glutathione peroxidase 4, ferroptosissuppressing CDGSH iron -sulfur domain 1 (CISD1), and mitochondrial regulating glycogen synthase kinase-313 phosphorylation with elevated p53, myosin heavy chain -13 isozyme, I kB phosphorylation, and solute carrier family 7 member 11 (SLC7A11) as well as unchanged SLC39A1, SLC1A5, and ferroptosissuppressing protein 1 following BSO challenge, all of which, except glutamine transporter SLC7A11 and p53, were abrogated by metallothionein. Inhibition of CISD1 using pioglitazone nulli fi ed GSH-offered bene fi t against BSO-induced cardiomyocyte ferroptosis and contractile and intracellular Ca 2 + derangement. Taken together, these fi ndings support a regulatory modality for CISD1 in the impedance of ferroptosis in metallothionein-offered protection against GSH depletion -evoked cardiac aberration.